Oyster Point Pharma, Inc. - OYST STOCK NEWS

Oyster Point Pharma will participate virtually in the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 10:30 A.M. ET. This biopharmaceutical company focuses on developing first-in-class therapies for ophthalmic diseases. Recently, they received FDA approval for their product TYRVAYA^TM (varenicline solution) Nasal Spray. The live webcast can be accessed via the company’s website. They aim to address unmet needs in eye care through innovation and collaborations.

Oyster Point Pharma (OYST) reported its Q4 2021 results, revealing a net product revenue of $1.2 million from TYRVAYA™ Nasal Spray and an additional $5.4 million from a license agreement with Ji Xing Pharmaceuticals. The FDA approved TYRVAYA for dry eye disease treatment on October 15, 2021, with over 5,500 prescriptions written by 1,900 eye care professionals by year-end. Despite an increase in expenses leading to a net loss of $42.1 million or $1.61 per share, the company remains focused on expanding its commercial efforts and ongoing research initiatives.

Oyster Point Pharma (Nasdaq: OYST) announced that TYRVAYA (varenicline solution) Nasal Spray has been added to Express Scripts' National Preferred, Basic, and High-Performance Formularies, effective February 19, 2022, impacting approximately 26 million lives. This approval follows the FDA's endorsement of TYRVAYA on October 15, 2021, as a treatment for dry eye disease. TYRVAYA, available since November 2021, uniquely addresses dry eye symptoms, affecting an estimated 38 million people in the U.S.

Oyster Point Pharma (Nasdaq: OYST) is set to report its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. Following the announcement, the company will host a live audio webcast and conference call at 4:30 p.m. ET. The company is focused on first-in-class pharmaceutical therapies aimed at treating ophthalmic diseases, having received FDA approval for TYRVAYA™ in October 2021. Additionally, they continue to expand their research pipeline through various collaborations.

Oyster Point Pharma, Inc. (Nasdaq: OYST) announced the grant of non-qualified stock options totaling 90,800 shares to seven new employees as part of its 2021 Inducement Incentive Plan. The options have an exercise price of $17.65, the company's closing price on the grant date, and will vest over four years. This grant was approved by the Compensation Committee to incentivize new talent in line with Nasdaq Listing Rule 5635(c)(4). Oyster Point is focused on ophthalmic diseases and recently received FDA approval for TYRVAYA™ nasal spray for dry eye disease.

Oyster Point Pharma, Inc. (Nasdaq: OYST) announced its participation in two upcoming virtual investor conferences. The 11th Annual LifeSci Partners Corporate Access Event will take place on January 5, 2022, followed by the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 PM EST. A live webcast for the J.P. Morgan conference will be accessible on the company’s website for 30 days. The company focuses on developing first-in-class therapies for ophthalmic diseases and recently received FDA approval for TYRVAYA^TM Nasal Spray for dry eye disease.

Oyster Point Pharma (Nasdaq: OYST) announced its inclusion in the Nasdaq Biotechnology Index, effective December 20, 2021. This index tracks performance of biotechnology and pharmaceutical securities listed on Nasdaq. The company's product, TYRVAYA (varenicline solution) Nasal Spray, is FDA-approved for treating dry eye disease, positioning it within a growing market. TYRVAYA leverages the trigeminal nerve to enhance tear production, with common side effects being sneezing and throat irritation. This addition to the index may enhance visibility and potentially investor interest.

Oyster Point Pharma (Nasdaq: OYST) will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on December 2, 2021. The biopharmaceutical company focuses on developing therapies for ophthalmic diseases. Recently, in October 2021, Oyster Point received FDA approval for TYRVAYA™ Nasal Spray to treat dry eye disease. The company is expanding its research pipeline through internal innovations and collaborations, aiming to address unmet patient needs in eye care.

Oyster Point Pharma (Nasdaq: OYST) has promoted Barry Rosenfeld to General Counsel and Raegan A. McClain to Chief Compliance Officer, enhancing its executive leadership team.

President and CEO Jeffrey Nau highlighted their extensive experience in the pharmaceutical industry as crucial for advancing the company's strategy, particularly in commercializing TYRVAYA (varenicline solution) Nasal Spray for dry eye disease. The company is committed to improving its pipeline and addressing patient needs in eye care.